Table 4:

Frontline CLL treatment regimens ranked by prevalence and stratified by diagnosis year

	2008		2014
	Regimen	N (%*)	Regimen	N (%*)
All Cases
Most common	FCR	67 (25.8)	BR	133 (35.5)
2nd most common	R monotherapy	35 (14.7)	R monotherapy	58 (14.8)
3rd most common	FR	30 (10.2)	FCR	52 (11.9)
4th most common	Chlorambucil +/−	26 (9.5)	Ibrutinib	34 (8.4)
Age < 70 at diagnosis
Most common	FCR	53 (40.7)	BR	89 (42.5)
2nd most common	FR	20 (13.2)	FCR	51 (19.9)
3rd most common	R monotherapy	11 (7.7)	Ibrutinib	23 (10.5)
4th most common	CVP +/− R	<11	R monotherapy	26 (9.8)
Age ≥ 70 at diagnosis
Most common	R monotherapy	24 (21.9)	BR	44 (25.4)
2nd most common	Chlorambucil +/−	17 (12.8)	R monotherapy	32 (22.2)
3rd most common	Other	13 (11.2)	Other	11 (12.6)
4th most common	R + anything else	<11	Obinutuzumab	16 (11.4)
Charlson Comorbidity Score = 0
Most common	FCR	56 (31.8)	BR	96 (39.1)
2nd most common	FR	25 (12.7)	FCR	41 (13.7)
3rd most common	R monotherapy	20 (11.6)	R monotherapy	39 (13.0)
4th most common	Chlorambucil +/−	16 (7.8)	Ibrutinib	24 (8.9)
Charlson Comorbidity Score 1 or more
Most common	R monotherapy	15 (21.5)	BR	37 (28.0)
2nd most common	Chlorambucil +/−	<11	R monotherapy	18 (18.7)
3rd most common	FCR	<11	Obinutuzumab	13 (12.8)
4th most common	CVP +/− R	<11	Ibrutinib	<11

Abbreviations: CLL, chronic lymphocytic leukemia; FCR, fludarabine, cyclophosphamide, and rituximab; BR, bendamustine and rituximab; R, rituximab; FR, fludarabine and rituximab; CVP, cyclophosphamide, vincristine, and prednisone.

^*Percentages are weighted by sampling fraction to reflect the SEER 14 population from which the data was obtained

To protect patient confidentiality only the 4 most common regimens are presented and any cell sizes <11 have been suppressed.